{"commentary":{"count":381,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":164,"podcast":110,"youtube":105,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04988295\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MARIPOSA-2","nct_id":"NCT04988295","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mariposa-2-nct04988295. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"MARIPOSA-2","arms":[{"description":"LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression.","label":"Arm A: LACP/ACP-L","type":"EXPERIMENTAL"},{"description":"Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.","label":"Arm B: CP (Carboplatin and Pemetrexed)","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.","label":"Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)","type":"EXPERIMENTAL"},{"description":"Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression.","label":"Arm A2 (Extension Cohort): ACP-L","type":"EXPERIMENTAL"},{"description":"Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.","label":"Arm C2 (Extension Cohort): ACP","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-07-03","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":776,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lazertinib","type":"DRUG"},{"name":"Amivantamab","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-07-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)"},{"measure":"Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","timeFrame":"up to 4 years 10 months"},{"measure":"Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review","timeFrame":"Up to 4 years 10 months"}],"references":[],"start_date":{"date":"2021-11-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","url":"https://clinicaltrials.gov/study/NCT04988295"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mariposa-2-nct04988295"}